Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $27.71 Average PT from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been given an average recommendation of “Hold” by the twenty-eight research firms that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $27.1739.

SRPT has been the subject of several analyst reports. Royal Bank Of Canada raised their price target on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a research note on Thursday, March 26th. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Citigroup boosted their price objective on Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research note on Thursday, March 26th.

Sarepta Therapeutics Stock Down 0.9%

Shares of SRPT opened at $16.80 on Friday. The company has a market capitalization of $1.77 billion, a PE ratio of -17.50, a PEG ratio of 0.19 and a beta of 0.26. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $43.92. The stock’s 50-day moving average price is $19.99 and its two-hundred day moving average price is $19.92. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $0.98 by $2.18. The company had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($3.42) earnings per share. On average, analysts anticipate that Sarepta Therapeutics will post 3.69 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director owned 1,765 shares in the company, valued at $30,040.30. The trade was a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.90% of the stock is currently owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently made changes to their positions in SRPT. Kestra Advisory Services LLC bought a new position in Sarepta Therapeutics in the fourth quarter worth approximately $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $25,000. Ancora Advisors LLC grew its position in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Allworth Financial LP increased its stake in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after buying an additional 1,256 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.